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The cellular uptake and the intracellular synthesis/
degradation of anandamide are crucial steps for
controlling its extracellular level and the duration of
its activity. Although the biosynthesis and breakdown
of anandamide are well understood, little is known
about the mechanisms underlying its intracellular
transport. Here, we investigated the presence of
a potential carrier-mediated trafficking of ananda-
mide within the cytosol, using a biotinylated analog
as a tool to catch by affinity chromatography ananda-
mide-interacting proteins. The identity of two of these
anandamide-binding proteins, Hsp70 and serum
albumin, was determined by mass spectrometry,
confirmed by western blotting and confocal micros-
copy, and further validated through an anandamide-
binding assay. These findings suggest that the traf-
ficking of anandamide from the plasma membrane
to the internal compartments of a cell occur via a non-
vesicular mechanism mediated by cytosolic carriers.
INTRODUCTION
The endogenous cannabinoid anandamide (N-arachidonoyle-
thanolamide, AEA) has been implicated as a local mediator in
several functions, including proliferation, growth arrest, differen-
tiation, and death of the cells (Berghuis et al., 2005; Casanova
et al., 2003; Maccarrone et al., 2003; Paradisi et al., 2008). Like
the pharmacologically active lipids present in Cannabis sativa
preparations, AEA elicits its effects primarily through specific
plasma membrane receptors, including type 1 and type 2 canna-
binoid receptors (CB1R and CB2R) (Matsuda et al., 1990; Munro
et al., 1993), and possibly GPR55, a purported CB3 receptor
(Lauckner et al., 2008). CB1R and CB2R are expressed in almost
all of the body’s districts. Moreover, AEA also acts as a true
endovanilloid by binding the transient receptor potential vanilloid
1 (Starowicz et al., 2007), and as a ligand of the a and g isoforms
of the nuclear peroxisome proliferator-activated receptors
(PPARs) (Sun and Bennett, 2007). Thus, it is not surprising that
a modulatory role of AEA has been demonstrated in the nervous,
immune, cardiovascular, and reproductive systems (Di Marzo,
2008; Klein, 2005; Piomelli, 2003; Wang et al., 2006).624 Chemistry & Biology 16, 624–632, June 26, 2009 ª2009 ElsevieLike for most paracrine mediators, the action of AEA is deter-
mined by its extracellular concentration that is controlled, in turn,
by the rate of its synthesis and degradation. Because both
biosynthetic and hydrolytic enzymes, N-acylphosphatidyletha-
nolamine (NAPE)-hydrolyzing phospholipase D (NAPE-PLD)
and fatty acid amide hydrolase (FAAH), respectively, are intracel-
lularly located (Desarnaud et al., 1995; Oddi et al., 2005; Ueda
et al., 2005), a transport system for the rapid and efficient traf-
ficking of AEA from and to these topographically separated sites
can be expected. Several studies supported the notion that the
migration of extracellular AEA within the cell is indeed a multistep
process that consists of at least four phases: (i) adsorption to the
plasma membrane, (ii) transmembrane movement, (iii) desorp-
tion from the plasma membrane, and (iv) intracellular trafficking,
accumulation, and hydrolysis (Glaser et al., 2005; McFarland and
Barker, 2004). At present, there is considerable controversy
regarding the first two events—the binding to, and the transport
across, the plasma membrane—because it is not yet established
whether they occur via a protein-dependent or independent
mechanism (Fegley et al., 2004; Fowler et al., 2004; Glaser
et al., 2003; Kaczocha et al., 2006; McFarland et al., 2004; Moore
et al., 2005). In any case, the intracellular transport of AEA, which
is slow because of the low solubility of this compound in water,
should be facilitated by a transport system, which likely involves
either vesicles or soluble carrier proteins, or a combination of the
two (Deutsch et al., 2001; Fowler et al., 2004; Glaser et al., 2003;
Hillard and Jarrahian, 2003; McFarland et al., 2004; Ortega-
Gutierrez et al., 2004; Ruiz-Llorente et al., 2004). Although
some evidence in support of a vesicular pathway involving cav-
eolae-related endocytosis (McFarland et al., 2004) and lipid
droplets (Oddi et al., 2008) has been presented, as yet no direct
evidence exists for a nonvesicular transport mediated by cyto-
solic carrier(s) specific for AEA.
To explore the possibility that AEA intracellular transporter(s)
are present in the cytosol, we recently developed and character-
ized a biotinylated analog of AEA, b-AEA (Fezza et al., 2008; Oddi
et al., 2008), which fully mimics the transport and intracellular
accumulation of AEA (Fezza et al., 2008; Oddi et al., 2008).
Here, b-AEA was used as a ‘‘bait’’ for affinity purification using
avidin-based chromatography of AEA-interacting molecules
from extracts of murine keratinocyte cytosols. The AEA-binding
proteins were separated by multidimensional PAGE and were
identified by mass spectrometry (MS). Using these approaches,
we identified two proteins, serum albumin and heat shock
protein 70.2 (Hsp70.2), as cytosolic AEA-binding proteins, thusr Ltd All rights reserved
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mechanism involved in the intracellular trafficking of ananda-
mide.
RESULTS
Identification of AEA-Binding Activity within the Cytosol
In preliminary experiments, we attempted to determine if the
epidermal cytosol contained AEA-binding sites. We found that
cytosol preparations could bind this endocannabinoid up to
about 70 fmol/mg protein. The protein nature of the AEA-binding
sites was indicated by their susceptibility to proteolytic digestion
by protease K and their resistance to DNase I, ribonuclease A,
and pancreatic lipase (Figure 1A).
Figure 1. Identification of AEA-Binding Sites within the Cytoplasm
(A) Analysis of the molecular nature and substrate specificity of the [3H]AEA-
binding sites in the cytosolic fractions of mouse keratinocytes. Cytosolic
preparations were incubated with 2 nM [3H]AEA and then incubated with
protease K (PK), DNase I (DNase), RNase A, pancreatic lipase C (Lipase),
unlabelled AEA, 2-arachidonoylglycerol (2-AG), N-palmitoylethanolamine
(PEA), N-arachidonoyldopamine (NADA), arachidonic acid (AA), or two AEA
uptake inhibitors, OMDM1 and VDM11. Results are expressed as percentage
of untreated cytosol (Ctrl, 100% = 68 ± 5 fmol/mg protein).*p < 0.05 versus
Ctrl; **p < 0.01 versus Ctrl. Error bars represent standard error of the mean
(SEM) of at least two independent experiments, each performed in triplicate.
(B) Partial purification of AEA-binding proteins by gel-filtration chromatog-
raphy. Cytosolic extracts were eluted on a gel-filtration column (Zorbax
GF-450), and the resulting fractions were analyzed for protein content (B)
and [3H]AEA-binding activity (-).Chemistry & Biology 16,In order to investigate the specificity of the AEA-binding
activity, competitive experiments were performed. Cytosol prep-
arations were incubated with [3H]AEA (2 nM) in the presence of
a 50-fold excess of structurally related, unlabelled compounds
(Figure 1A). As expected, the binding of 2 nM [3H]AEA to cyto-
solic protein(s) was reduced (down to 10%) by an excess of
unlabelled AEA. A less pronounced, yet significant, 50%
displacement was observed using the AEA congenerN-arachido-
noyldopamine. However, 2-arachidonoylglycerol and N-palmi-
toylethanolamine could displace only 15%–20% of the bound
[3H]AEA. Finally, arachidonic acid, a catabolic product of AEA,
and two different AEA uptake inhibitors, (S)-10-(4-hydroxyben-
zyl)-oleoylethanolamide (OMDM1) and N-(2-methyl-4-hydroxy-
phenyl)-arachidonamide (VDM11) (De Petrocellis et al., 2000;
Ortar et al., 2003), showed only 5% displacement of bound
[3H]AEA (Figure 1A). These results suggest the presence of AEA-
binding proteins within the cytosol, which appear to be different
from those that are responsible for the transport of AEA across
the plasma membrane.
Gel Filtration and [3H]AEA-Binding Activity
Analysis of the fractions derived from a gel filtration column sug-
gested that [3H]AEA eluted after 17 min (Figure 1B) with an elution
profile only partially superimposable to that of the cytosolic
proteins, indicating that AEA was primarily associated with
specific protein(s) with an apparent molecular weight of 63 ±
25 kDa (Figure 1B and Table 1). Interestingly, the presence of
a shoulder in the elution profile (fraction 6) and of a minor peak in
fraction 11 were also noted, suggesting that AEA might bind to
a variety of cytosolic proteins ranging from660 kDa to < 43 kDa.
However, only the most active fractions (7–9) were further
analyzed in this study.
Nano-LC ESI-MS/MS Identification
of Affinity-Purified AEA-Binding Proteins
The most AEA-binding-rich fractions (7–9), amounting to 65%
of the total AEA-binding activity, were pooled, labeled by incuba-
tion with 20 mM b-AEA for 1 hr, and loaded onto a monomeric
avidin column for further purification by affinity chromatography.
The b-AEA-binding molecules retained by avidin were then
eluted by competition with biotin. Then, such proteins were
further separated by 2D PAGE (Figure 2). By comparing the 2D
PAGE profiles of the affinity-purified samples with a mock-puri-
fied control (Figure 2A), we identified several specific spots
(Figure 2B). Among these, we focused on three major spots
(labeled 4, 5, and 6) of apparent molecular mass of 50–70 kDa.
Our analysis did not include low abundance protein spots
because of anticipated difficulties in obtaining satisfactory
protein identification by MS. These spots were excised from
the gel for tryptic digestion, and the resulting peptides were
analyzed by nano-liquid chromatography electrospray ionization
tandem mass spectrometry (nano-LC ESI-MS/MS). Peptide
masses were searched using the Mascot engine with a tolerance
of 300 ppm (for more details on MS spectra, see Supplemental
Data available online). The database search resulted in heat
shock protein 70.2 (Hsp70.2) (spot 4; pI = 5.58; Mr = 69,684 Da),
with 6% sequence coverage (number of peaks matched = 3) and
a Mowse score of 82 (p < 0.05; Figure 2D), and serum albumin
(spot 5; pI = 5.75 ; Mr = 68648 Da), with 2% sequence coverage624–632, June 26, 2009 ª2009 Elsevier Ltd All rights reserved 625
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0.05; Figure 2C). The analysis of spot 6 led to a protein score of
35 and therefore its identity remained elusive. It is important to
note that the MS analysis of each spot led to fragments belonging
to single proteins, suggesting that the analyzed spots contained
only a single protein. The coordinates (molecular mass and pI) of
the detected spots were estimated by interpolation with standard
proteins, and were in good agreement with the nominal mass and
calculated isoelectric point values of the proteins identified by MS
(Figure 2B and Table 2). Notably, serum albumin has been
described to bind AEA in vitro with high affinity (Bojesen and Han-
sen, 2003; Giuffrida et al., 2000), thus supporting our proteomic
analysis. The results of the MS analysis were confirmed by
western blotting analysis of the affinity-purified sample, per-
formed using commercially available antibodies against Hsp70
and serum albumin (Figure 2E). Moreover, we confirmed by
confocal microscopy the expression and the intracellular locali-
zation of both Hsp70 and serum albumin in epidermal keratino-
cytes (data not shown). Although our MS data, together with
the experimental molecular mass and pI, point toward Hsp70.2,
which is constitutively expressed in the cell cytoplasm in most
tissues, including epidermis, it could not be excluded that other
members of Hsp70 family—a group of highly related chaperonins
that have remarkable sequence identity—might bind AEA, likely
through their well-conserved binding domains.
In Vitro Analysis of Hsp70-AEA Interaction
In order to confirm the physical interaction between Hsp70.2 and
AEA, we developed a straightforward method consisting of
a ‘‘pull-down’’ assay adapted for protein-lipid interaction studies.
Hsp70.2 is highly conserved between human and mouse,
showing remarkable homology with 96% amino acid identity.
Human and mouse serum albumin is also very conserved, with
over 71% identity. Therefore, these high levels of identity allowed
Table 1. Purification of Intracellular Anandamide-Binding Sites
from Skin Keratinocytes
Fraction
Total Activity
(fmol [3H]AEA) Protein (mg)
Specific Activity
(fmol [3H]AEA/mg)
Cytosol 60.8 0.9 67.5
1 NDa ND ND
2 ND ND ND
3 ND 3.4 ND
4 ND 13.9 ND
5 0.8 26.9 29.7
6 2.8 50.6 55.3
7 7.8 108.9 71.6
8 17.7 141.5 125.1
9 13.3 137.9 96.4
10 5.4 120.9 44.7
11 6.2 117.4 52.8
12 2.1 91.2 23.0
13 0.7 70.0 10.0
14 0.2 30.1 6.6
15 ND 2.0 ND
a ND indicates not detectable626 Chemistry & Biology 16, 624–632, June 26, 2009 ª2009 Elsevieus to shift our study from mouse to human models. After 1 hr incu-
bation at various [3H]AEA concentrations, AEA binding to human
Hsp70 was determined by counting the radioactivity retained by
the resin-bound proteins. The procedure was first validated by
analyzing AEA affinity for human serum albumin (HSA), because
it is known that albumin binds AEA with a Kd value in the nanomo-
lar range at 23C (Bojesen and Hansen, 2003; Giuffrida et al.,
2000). We found that although the resin per se did not retain
a significant amount of radioactivity, 15 nmol resin-adsorbed
HSA was able to bind [3H]AEA in a concentration-dependent
manner, typical of a saturable process (Figure 3A), with apparent
Kd and Bmax values of 0.8 ± 0.1 mM and 2.3 ± 0.2 nmol/mg
protein, respectively. Next, the assay for the detection of
Hsp70-AEA complexes was carried out with 12 nmol resin-bound
protein. As shown in Figure 3B, AEA exhibited saturable binding
also to Hsp70. The experimental data were fitted to a rectangular
hyperbola with an apparent Kd value of 3.7 ± 0.5 mM and a Bmax
of 1.9 ± 0.1 nmol/mg protein, indicating that Hsp70 binds AEA
with a 5-fold lower affinity than HSA.
Effect of Hsp70 Overexpression on AEA Uptake
in SH-SY5Y Cells
Because primary keratinocytes transfected with relatively poor
efficiency (<5%) (Leask et al., 1990), we assessed the effect of
Hsp70.2 overexpression on AEA uptake in human neuroblas-
toma SH-SY5Y cells transiently transfected with the expression
vector pcDNA-human Hsp70.2. After 24 hr, expression levels of
Hsp70.2 in the cells were assessed by immunofluorescence,
using an anti-Hsp70 antibody. Transfection efficiency, measured
as percentage of Hsp70.2-overexpressing cells, was 50%
(data not shown). We found that the overexpression of
Hsp70.2 increased 5-fold [3H]AEA uptake, from 0.40 ± 0.10
pmol/min per mg protein in mock-transfected cells to 2.12 ±
0.20 pmol/min per mg protein in Hsp70.2-transfected cells
(mean ± SEM; n = 6; p < 0.0001) (Figure 3C). As a control, the
addition of 5 mM OMDM-1 minimized the transport of AEA across
the cell membrane (Figure 3C).
Consistently with the affinity purification data, coimmunostain-
ing of exogenous Hsp70.2 and b-AEA showed a marked coloc-
alization of the two molecules (Figures 3D–3F). As indicated in
the merged picture (Figure 3F, arrowheads in the inset), an array
of b-AEA-positive tubular structures was also positive for
Hsp70.2. Moreover, a diffuse cytosolic distribution for both
substances was observed. Interestingly, tubular structures with
both Hsp70.2 and b-AEA stainings were observed in the close
proximity of plasma membrane (Figure 3D–3F, asterisks), sug-
gesting a potential interaction between these two molecules
also at the level of the cell membrane. Altogether, these experi-
ments indicate that Hsp70.2 enhances the rate of the cellular
uptake of AEA, possibly as a result of its direct interaction with
this lipid.
DISCUSSION
Recently, increasing attention has been directed toward AEA
transport across the cell membrane, because of its role in the
regulation of the biological activity of AEA (Dainese et al., 2007;
Fowler et al., 2005; McFarland and Barker, 2004). However,
despite its pathophysiological relevance, there is as yet nor Ltd All rights reserved
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(A–D) Representative bidimensional electrophoresis (2D-PAGE) gels of mock-purified (A) and affinity-purified (B) samples. Nonspecifically and specifically eluted
proteins were resolved by 2D-PAGE on nonlinear pH 3–11 isoelectrofocusing strips, followed by separation on a 12% SDS-PAGE gel in the second dimension.
Proteins were visualized by colloidal Coomassie staining. In the insets, high-magnification views of the gels of a selected area are shown. Circled spots indicate
proteins further subjected to mass spectrometry. Mascot search results and probability plots corresponding to albumin (C) and Hsp70 (D).
(E) Western blotting analysis of cytosol (cyt) and affinity-purified sample (Pur), using antibodies against serum albumin and Hsp70.consensus on how this process occurs, i.e., by (i) passive diffu-
sion, (ii) facilitated diffusion, or (iii) a combination of both. Another
ill-defined issue is the mechanism whereby AEA detaches from
the plasma membrane and, subsequently, diffuses throughout
the cytoplasm, a process that is likely to represent the bottle-
neck of AEA metabolism (Forneris and Mattevi, 2008). Although
AEA, a neutral lipid, is sufficiently lipophilic to partition into the
membrane bilayers (log p = 5.1 [Oddi et al., 2008]), a simple, non-
ordered diffusion of AEA through the aqueous cytoplasm to
intracellularly located targets is unlikely to be fast enough to
account for the rate and the extent of intracellular accumulation
and metabolism of this endocannabinoid (Beltramo et al., 1997;
Hillard and Jarrahian, 2000; Jacobsson and Fowler, 2001; Mac-
carrone et al., 2000; Ortega-Gutierrez et al., 2004; Rakhshanet al., 2000). From this point of view, an ‘‘organized system’’
has been hypothesized for the efficient delivery of AEA to its
hydrolase FAAH, and/or to other potential internal targets (Hillard
and Jarrahian, 2003). Experimental evidence in support of such
an organized system has been indeed provided, suggesting
the involvement of a lipid rafts/caveolae endocytic pathway for
the transmembrane transport of AEA, as well as for its recycling
after catabolism (McFarland et al., 2004). Moreover, a dynamic
interaction has been recently described between AEA and adi-
posomes, lipid storage vesicles that could act as shuttles for
the transport of this lipid among intracellular compartments
(Oddi et al., 2008). Another unexplored possibility is that some
soluble proteins ferry AEA through the cytoplasm; this could
speed up its internalization, by analogy with what observed forTable 2. MS/MS-Identified Proteins in Affinity-Purified Samples
Spot
Number
Accession
Number Protein
Molecular Mass
(kDa) (Theoretical/
Experimental)
Isoelectric Point
(Theoretical/
Experimental)
MASCOT
Score
Peptides
Matched
Sequence
Coverage (%)
MS/MS
Sequences
4 gij123621 HSP70.2 69.7/67 5.58/5.0 82 3 6 R.IINEPTAAAIAYGLDK.K
R.FEELNADLFR.G
R.VAAKNAVESYTYNIK.Q
5 gij163310765 Albumin 68.7/67 5.75/5.2 90 1 2 K.LGEYGFQNAILVR.Y
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(A and B) AEA binding to 5 mg albumin (A) or Hsp70 (B) immobilized to 10 ml resin was determined by means of a batch method. The resin-adsorbed proteins were
incubated with varying concentrations of AEA for 30 min at 25C. Nonspecific adsorption of AEA to cellular membranes or cell supports was estimated by running
the identical experiments at 4C, and was subtracted from each data point. The lines drawn are the best fit of the data to one-site-binding hyperbola. Values
are means ± SEM of at least two independent experiments, each performed in triplicate. Overexpression of Hsp70.2 in SH-SY5Y cells.
(C) Effect of Hsp70.2 overexpression (Hsp70) versus control (Ctrl) on [3H]AEA uptake by SH-SY5Y cells, grown in the absence or in the presence of 5 mM OMDM1
(Hsp70 + OMDM-1). ***p < 0.0001 versus Ctrl.
(D–F) Double immunofluorescence of Hsp70.2 (red) and b-AEA (green). The superimposition of the two stainings revealed that Hsp70.2 and b-AEA colocalize in
tubular structures within the cytosol (arrowheads in the inset) or near to the plasma membrane (asterisks). The images are representative of three independent
experiments, and in each case five fields were examined. Scale bar, 10 mm.other lipids, including cholesterol (Soccio and Breslow, 2004),
ceramide (Hanada et al., 2003), and long-chain fatty acids (Fur-
uhashi and Hotamisligil, 2008). However, so far no evidence
exists for such a nonvesicular transport of AEA, primarily
because of methodological limitations in studying the movement
of AEA by the current radiometric-based techniques (Glaser
et al., 2005).
In the present study we sought to address this issue by em-
ploying a biotinylated analog of AEA, b-AEA (Fezza et al., 2008;
Oddi et al., 2008), as a valuable affinity chromatography tool.
Based on the well-characterized presence of the endocannabi-
noid system in the epidermis (Casanova et al., 2003; Maccarrone
et al., 2003; Paradisi et al., 2008), we decided to use keratino-
cytes as an experimental model to explore the presence of
constitutive intracellular AEA transporters. Moreover, because
epidermis is an avascular tissue mostly made of cells with poor
extracellular space (Fuchs, 1990), mouse epidermal keratino-
cytes represent a convenient source of cytosolic proteins virtu-
ally devoid of any contamination from blood proteins. In prelim-
inary experiments, we found that the cytosolic extracts
contained a specific AEA-binding activity associated with628 Chemistry & Biology 16, 624–632, June 26, 2009 ª2009 Elsevieproteins and insensitive to OMDM1 and VDM11, two well-char-
acterized inhibitors of AEA uptake (De Petrocellis et al., 2000; Or-
tar et al., 2003), suggesting that the cytosolic proteins involved in
intracellular AEA binding were different from those that are
responsible for the transmembrane transport of AEA. Interest-
ingly, we found that AEA binding was specifically inhibited by
N-arachidonoyldopamine (NADA) but not by 2-arachidonoylgly-
cerol, palmitoylethanolamine (PEA), or arachidonic acid, indi-
cating that ligand recognition by the cytosolic AEA carrier(s)
implies stringent structural determinants.
Next, by using affinity chromatography, we were able to
isolate several AEA-interacting proteins in the cytosolic extract
from mouse epidermal keratinocytes. Among these, we identi-
fied by MS the proteins corresponding to two major spots: serum
albumin and Hsp70.2. The identity of these proteins was subse-
quently confirmed by western blotting and immunofluorescence.
Concerning albumin, among the albuminoid gene family, con-
sisting of serum albumin (69.7 kDa), alpha-fetoprotein (47 kDa),
vitamin D binding protein, and alpha-albumin (afamin), only
alpha-fetoprotein and serum albumin match with the MS-identi-
fied peptide. Considering the experimental molecular mass ofr Ltd All rights reserved
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consists of serum albumin and not of alpha-fetoprotein.
However, due to their high homology, it could not be excluded
that alpha-fetoprotein might bind AEA. Albumin has been
demonstrated to bind AEA with high affinity in the extracellular
milieu (Bojesen and Hansen, 2003; Giuffrida et al., 2000), but
this is the first evidence that endogenous albumin interacts
with AEA within the cell. In fact, until now serum albumin has
been shown to bind and transport AEA only in blood, whereas
a role for albumin in the cytoplasm has not been considered. In
this context, it seems noteworthy that the endogenous synthesis
of albumin in human epidermis, as well as in human keratino-
cytes in culture, has been previously documented both at tran-
scriptional and translational level (Hasse et al., 2005; Katz
et al., 1970; Rabilloud et al., 1988). In agreement with these
studies, we confirmed by western blotting and confocal micros-
copy the expression and the intracellular localization of albumin
in epidermal keratinocytes, indicating that AEA-binding albumin
was endogenously expressed, and was not a contaminant from
serum. Therefore, besides binding and transporting AEA in
plasma and in the extracellular space, albumin seems to act
also as an intracellular AEA transporter (AIT). Taking into account
that variable levels of albumin have been found within the cytosol
of different cell lines, and that this protein is particularly ex-
pressed in actively metabolizing or developing tissues, it could
be proposed that albumin has a role in controlling the bioavail-
ability of AEA in multiple functional contexts. At present, very
few information exists regarding the structural aspects of the
interactions between HSA and AEA. As ethanolamide of arachi-
donic acid, AEA binds to albumin in only one high-affinity binding
site (Bojesen and Hansen, 2003), with a somewhat lower binding
constant than that seen for arachidonic acid, which, unlike AEA,
can bind to albumin at three different binding sites. These differ-
ences have been imputed to the fact that AEA is not only a neutral
molecule but it is also much larger than arachidonic acid.
However, a complete and reliable assignment of the AEA-
binding site on albumin is unsettled and will require further work.
The human Hsp70 family comprises at least eight unique gene
products that differ from each other by amino acid sequence,
expression level, and subcellular localization. Our MS data,
together with the experimental molecular mass and pI, point
toward Hsp70.2, which is constitutively expressed in the cell
cytoplasm in most tissues, including epidermis. However, as
stated for albumin, because Hsp70.2 shows high homology
with other members of Hsp70 family (for example, it displays
86% identity to heat shock cognate 70), it could not be excluded
that other members of this family might bind AEA, through their
conserved binding domains. In order to confirm the interaction
between Hsp70 and AEA, we developed an in vitro batch method
that has the limitation of recording AEA/Hsp70 complex forma-
tion after several washing steps, and thus not at equilibrium.
Consequently, the observed Kd and Bmax were only rough esti-
mates of the actual binding parameters. By utilizing pure
proteins, we found that Hsp70, alike HSA, was able to bind
AEA in a concentration-dependent manner, typical of a saturable
process, though with a lower affinity than HSA. More sophisti-
cated techniques, such as calorimetry (Gazzara et al., 1997),
surface chemistry (Ibdah et al., 1989), capillary electrophoresis
(Breyer et al., 2003), or resonance energy transfer (Drin et al.,Chemistry & Biology 16,2001), should be adapted in order to better quantify the binding
properties of Hsp70 toward AEA, and hence its suitability as
a physiological AIT. In this context, Hsp70 is able to interact
with lipids, including sterols and sphingolipids (Gacad and
Adams, 1998; Mamelak and Lingwood, 1997), through a binding
site that has been localized in the conserved, N-terminal
ATPase-containing domain (Mamelak and Lingwood, 1997).
Moreover, similar to other members of its family, Hsp70 is not
exclusively localized within the cytosol, but has also been found
in association with membrane lipids (Gehrmann et al., 2008; Uit-
tenbogaard et al., 1998). Here, we confirmed the intracellular
localization of Hsp70.2 by confocal microscopy, showing that
it has a predominant cytoplasmic staining partially overlapped
to that of b-AEA. In addition, we also observed costaining of
Hsp70.2 and b-AEA close to the plasma membrane, suggesting
that Hsp70.2 might interact with AEA also at this level.
During the revision process of this manuscript, a paper
appeared describing fatty-acid-binding proteins that, when
overexpressed, behave as intracellular proteins that bind AEA,
complementing the findings of our study (Kaczocha et al., 2009).
SIGNIFICANCE
Due to their role in the regulation of the extracellular tone of
AEA, both cellular uptake andmetabolism of AEA are crucial
steps for controlling the duration of its activity, and thereby
represent potential targets for the development of thera-
peutic strategies aimed at modulating the level of AEA in
several pathologies. Although the biosynthesis and break-
downof AEAwerewell understood, very little is known about
themechanismsunderlying its intracellular transport. Herein
we investigated the presence of a potential carrier-mediated
trafficking of AEA within the cytosol, using a biotinylated
analog of AEA, biotin-AEA, as a ‘‘bait’’ to isolate by affinity
chromatography its endogenous interacting proteins. From
the above-mentioned findings, it is conceivable that Hsp70,
perhaps assisted by serum albumin, may act as an AIT in
the cytosol, and as an ‘‘AEA chaperon’’ at the plasma
membrane, where it might promote the desorption of this
lipid, thus facilitating its transport through the cytoplasm.
Then, AEA can be delivered to specific compartments within
the cell, for example to the lipid droplets for accumulation, to
the endoplasmic reticulum for degradation (via FAAH), or
to the nucleus for transcriptional regulation (via PPAR-a/g).
In summary, this work provides the first evidence for the
existence of AEA intracellular transporters, which might
form a delivery system active in cytosol, plasma membrane,
nucleus, and endoplasmic reticulum, to rapidly and effi-
ciently assist the intracellular trafficking of AEA.
EXPERIMENTAL PROCEDURES
Reagents
All chemicals were of the purest analytical grade. [3H]AEA (205 Ci/mmol) was
from Perkin-Elmer Life Sciences (Boston, MA). AEA, HSA, bovine serum
albumin, human Hsp70 (cod. H7283) and the anion-exchange resin diethylami-
noethyl (DEAE)-Sepharose were from Sigma Chemical (St. Louis, MO). PEA
and NADA were from Tocris Cookson (Bristol, UK). Arachidonic acid,
OMDM1, and VDM11 were purchased from Cayman Chemical (Ann Arbor,
MI). The biotinylated analog of AEA, b-AEA, was synthesized and purified as624–632, June 26, 2009 ª2009 Elsevier Ltd All rights reserved 629
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purchased from Millipore Co. (Rome, Italy). Rabbit anti-Hsp70 (cod. sc-
33575) and anti-albumin (cod. sc-46290) polyclonal antibodies were obtained
from Santa Cruz Biotechnology (Santa Cruz, CA). Mouse anti-biotin mono-
clonal antibody, goat Alexa Fluor-conjugated secondary antibody, and
Prolong anti-fade kit were purchased from Molecular Probes (Eugene, OR).
The plasmid expressing human Hsp70.2 (pcDNA3-Hsp70.2) was a kind gift
of Dr. Antonio Rossi of the Institute of Neurobiology and Molecular Medicine
(National Research Council, Rome, Italy). LipofectAMINE 2000 was from Invi-
trogen Life Technologies. Culture media, sera, and supplements were ob-
tained from PromoCell (Heidelberg, Germany). All other chemicals were from
Sigma Chemical, unless otherwise indicated.
Epidermal Explantation
Twenty-five newborn mice (1–2 days old) were killed by cervical dislocation
after anesthesia and the skin was removed, rinsed in Ca2+/Mg2+-free phos-
phate-buffered saline (PBS), and incubated in 1% trypsin in PBS for 18 hr at
4C. Explanted skins were transferred to PBS at room temperature (RT) and
aspirated with a Pasteur pipette to loosen the epidermis, which was subse-
quently removed, using forceps and a tungsten needle, and extensively
washed with ice-cold PBS.
Extraction of Cytosolic Proteins
To isolate cytosolic proteins, epidermal mouse keratinocytes were explanted
from the skin of newborn mice. To this end, 25 newborn mice (1–2 days old)
were killed by cervical dislocation after anesthesia and the skin was removed,
rinsed in Ca2+/Mg2+-free PBS, and incubated in 1% trypsin in PBS for 18 hr at
4C. Explanted skins were transferred to PBS at RT and aspirated with a Pas-
teur pipette to loosen the epidermis, which was subsequently removed, using
forceps and a tungsten needle, and extensively washed with ice-cold PBS.
The cell extracts were resuspended in hypotonic buffer (5 mM Tris-HCl [pH
7.4], 10 mM KCl, 5 mM EDTA, 1 mM 4-[2-aminoethyl]benzenesulfonyl fluoride,
and 1 mM DTT) and lysed on ice using a loose-fitting Dounce homogenizer.
After low-speed centrifugation to remove nuclei and intact cells, the cytosolic
fraction was prepared by centrifuging supernatants at 250,000 x g for 2 hr at
4C. The cytosol samples were dialyzed against PBS for 5 hr at 4C, and the
protein concentration was measured by the Bradford assay kit (Bio-Rad,
Hercules, CA).
[3H]AEA-Binding Assay by Ultrafiltration
The estimation of AEA binding to cytosol extracts was performed by adapting
a method based on centrifugal ultrafiltration (Menguy et al., 1998). In a typical
binding experiment, 0.5 ml cytosol samples containing 1.5 mg protein/ml were
incubated with an equal volume of [3H]AEA in PBS (final concentration, 2 nM;
specific activity, 205 Ci/mmol). The mixture was incubated for 30 min at RT.
Preliminary experiments had shown that equilibrium was attained under these
conditions. Nonspecific binding was checked by parallel incubations in the
presence of a 200-fold molar excess of unlabelled AEA. After incubation,
samples were rapidly filtered through YM-10 Centricon tubes (molecular
weight cut-off, 10 kDa), to concentrate the macromolecules contained in the
sample, while free [3H]AEA flowed by. The retained fraction (100 ml) was then
washed three times with PBS (5 ml per wash) to remove unbound [3H]AEA.
The amount of protein-bound AEA was calculated by measuring the radioac-
tivity bound to the final concentrate. [3H]AEA-binding activity was expressed
as fmol [3H]AEA bound per milligram protein. Due to variability between
batches of Centricon devices, each lot was tested in the absence of proteins,
to ensure that free AEA was efficiently flushed away after the washing steps.
Each value was determined in triplicate and was corrected for nonspecific
binding performed in parallel experiments. To test the sensitivity of [3H]AEA
binding in the cytosolic fraction to enzymatic digestion with protease K, DNase
I, ribonuclease A, and pancreatic lipase, each enzyme was added to the
samples at a concentration of 1 U/ml, and was incubated for 1 hr at 37C.
Then, [3H]AEA binding was assayed as described above.
Fractionation by Gel Filtration
Size-exclusion high-performance liquid chromatography measurements were
performed on a PE Series 200 System (Perkin-Elmer) using a Zorbax GF-450
gel-filtration column (Agilent Technologies, Santa Clara, CA) that allows sepa-630 Chemistry & Biology 16, 624–632, June 26, 2009 ª2009 Elsevieration within a range from 10 to 1000 kDa. Cytosol (150 ml) was incubated with
2 nM [3H]AEA and fractionated on the Zorbax GF-450 column using PBS as
eluent, at RT and a flux rate of 1 ml/min. Protein concentration and radioactivity
of the collected fractions were monitored using an ultraviolet-visible detector
and a radiodetector, respectively. Protein size was determined by comparison
with the following gel-filtration grade molecular mass standards (GE Health-
care, Uppsala, Sweden): ovalbumin (43 kDa), albumin (67 kDa), aldolase
(158 kDa), and thyroglobulin (669 kDa).
Biotin-Affinity Chromatography
The cytosolic fraction was preliminarily cleared of endogenous biotinylated
proteins by passing through a monomeric avidin column (Pierce, Rockford,
IL), equilibrated in PBS. The cleared extract was mixed with 20 mM b-AEA,
incubated for 30 min at RT, and applied to freshly prepared monomeric avidin
column. After sample application, the avidin column was washed extensively
with PBS, until the absorbance value at 280 nm reached the baseline. Then,
bound proteins were competitively eluted with PBS containing 2 mM biotin,
and were concentrated on YM-10 Centricon filters for further analysis.
Nonspecific elution from the affinity column was identified by collecting the
eluate from the column loaded with cleared cytosol, but without added b-AEA.
Two-Dimensional PAGE
2D-PAGE was performed using ready-made immobilized pH gradient (IPG)
strip gels (7 cm IPG strips [pH 3–11]) from Bio-Rad. Each sample was applied
onto an IPG gel by in-gel rehydration overnight. Isoelectric focusing was
carried out in a Protean IEF cell apparatus (Bio-Rad), essentially as described
elsewhere (Gorg et al., 2000). 2D-PAGE gels were stained with colloidal Coo-
massie (18% (v/v) ethanol, 15% (w/v) ammonium sulfate, 2% (v/v) phosphoric
acid, 0.2% (w/v) Coomassie G-250) for 48 hr, and were destained with distilled
water. Stained 2D-PAGE gels were scanned with ImageMaster VDS-CL
(Amersham Biosciences, Uppsala, Sweden). Image analyses were performed
using ImageMaster 2D Elite software (Amersham Biosciences). After spot
detection, background subtraction was performed using mode of nonspot
option, normalization was performed using total spot volume, and matching
between gels of the same format was performed through user seeds match.
For isoelectric point and molecular mass calibrations, the 2D-PAGE internal
standards from Bio-Rad were used, performing IEF, SDS-PAGE, staining,
and scanning as indicated above.
Nano-LC ESI-MS/MS
Protein identification using nano-LC ESI-MS/MS was conducted by the
Proteome Factory (Proteome Factory AG Berlin, Germany; http://www.
proteomefactory.com). The MS system consists of an Agilent 1100 NanoLC
system (Agilent, Germany), PicoTip emitter (New Objective, USA), and an
Esquire 3000 plus ion trap MS (Bruker, Bremen, Germany). Protein spots
were in-gel digested by trypsin (Promega, Mannheim, Germany) and applied
to nano-LC-ESI-MSMS. After trapping and desalting the peptides on enrich-
ment column (Zorbax SB C18, 0.3 3 5 mm, Agilent) using 1% acetonitrile/
0.1% formic acid solution for 5 min, peptides were separated on Zorbax
300 SB C18, 75 mm3 150 mm column (Agilent) using an acetonitrile/0.1% for-
mic acid gradient from 5% to 40% acetonitrile within 40 min. MS spectra were
automatically taken by Esquire 3000 plus according to manufacturer’s instru-
ment settings for nano-LC-ESI-MS/MS analyses. The peptide mass mapping
was performed on an ESI-TRAP, and was analyzed by LC-MS/MS. The
matched peptides were searched using Mascot (http://www.matrixscience.
co.uk), based on the NCBInr database and taking Mus musculus as the
taxonomy. The searching parameters were: an MS/MS tolerance of ± 0.5 Da,
one missed cleavage site, fixed modifications of carbamidomethyl, peptide
tolerance of ± 0.5 Da, peptide charge of 1+ 2+ 3+, monoisotopic, and ESI-TRAP
instrument. Probability-based Mowse scores were obtained using the same
software, by comparing search results with an estimated random match
population, and results were reported as 10*log(P), where P is the absolute
probability. Individual ions scores greater than 40 indicate identity or extensive
homology (p < 0.05). Protein scores were derived from ions scores as a non
probabilistic basis for ranking protein hits. Only significant hits, as defined by
the Mascot probability analysis (p < 0.05), were accepted. If multiple significant
hits were found for a protein, only the highest scoring hit was listed in Table 2.r Ltd All rights reserved
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Cytosolic extracts (50 ml) and affinity purified sample (5% of the total amount)
were subjected to western blotting according to standard procedures (Mac-
carrone et al., 2003), and serum albumin and Hsp70 were immunodetected
using antibodies that are validated for detection of these proteins of both
human and mouse origin.
[3H]AEA-Binding Assay by DEAE
For AEA-binding studies with HSA and Hsp70, a variant of the conventional
pull-down assay was used. This method exploits the ability of DEAE resin to
bind proteins but not free lipids. Purified and delipidated proteins (5 mg, corre-
sponding to 15 nmol and 12 nmol HSA and Hsp70, respectively) were ad-
sorbed to 30 ml slurry DEAE sepharose (50%, v/v) by incubating the suspen-
sion in 20 mM Tris-HCl (pH 7) for 15 min at RT. Then, DEAE-adsorbed
proteins were incubated with various concentrations of [3H]AEA for 1 hr at
RT, and the suspension was vortexed every 10 min. The final volume was
200 ml, and the total concentration of methanol did not exceed 1%. At the
end of the incubation, 1 ml ice-cold 20 mM Tris-HCl was added to stop the
reaction, and the resin was collected by centrifuging at 7000 x g for 5 min,
and washed twice in the same way. Then, DEAE was resuspended in 500 ml
20 mM Tris-HCl and added to a vial containing scintillation liquid, and radioac-
tivity was measured in a beta-counter analyzer. Each value was determined in
triplicate and was corrected against a blank (no protein added) assayed in
parallel. The counts of blanks were never more than 7% of the total amount
of ligand added. Binding data for HSA and Hsp70 were elaborated through
nonlinear regression analysis, using the Prism 4 program (GraphPad Software
Inc., San Diego, CA), in order to calculate apparent dissociation constant (Kd)
and maximum binding (Bmax) of [3H]AEA.
Cell Transfection and Immunofluorescence
Cell transfection and double immunofluorescence techniques are detailed in
Supplemental Data.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures and four
figures and can be found with this article online at http://www.cell.com/
chemistry-biology/supplemental/S1074-5521(09)00151-3.
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